Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions

Experimental and Clinical Endocrinology and Diabetes

Volumn 111, Issue 5, 2003, Pages 262-266

  Schatz, Helmut ^a   Schoppel, K ^b   Lehwalder, D ^c   Schandry, R ^d  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b NOVARTIS PHARMA GMBH   (Germany)

^c MERCK KGAA   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

General practice study; Metformin; Nateglinide; Safety; Tolerability

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT;

ABDOMINAL DISCOMFORT; ADULT; AGED; AORTA VALVE REGURGITATION; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CORONARY ARTERY DISEASE; DIABETES CONTROL; DIABETIC COMA; DIARRHEA; DISEASE DURATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FEMALE; FLATULENCE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENERAL PRACTICE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; POSTPRANDIAL STATE; PRIORITY JOURNAL; SYMPTOM; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FAMILY PRACTICE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PHENYLALANINE; POSTPRANDIAL PERIOD; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 0042425944     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-41752     Document Type: Article

References (12)

1. Füchtenbusch M, Standl E, Schatz H. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2000; 108: 151-163
2. Halas CJ. Nateglinide. Am J Health-Syst Pharm 2001; 58: 1200-1205
3. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-1583
4. Hanif W, Kumar S. Nateglinide: a new rapid-acting insulinotropic agent. Expert Opin Pharmacother 2001; 2: 1027-1031
5. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000; 23: 1660-1665
6. Keilson L, Mather S, Walter YH, Subramanian S, McLeod JF. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000; 85: 1081-1086
7. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18: 258-268
8. Marre M, Whatmough I, Ball M, Guitard C. Nateglinide added to metformin offers safe and effective treatment for type 2 diabetes. Diabetes 2000; 49 (Suppl1): 1517
9. Nationale Versorgungs-Leitlinie Diabetes mellitus Typ 2. http://www.leitlinien.de/versorgungsleitlinien/index/diabetes/pdf/nvldiabetes. 2002
10. 1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44: 968-983
11. The DECODE study group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of diagnostic criteria in Europe. Lancet 1999; 354: 617-621
12. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853